

# EMBRACING NATURE'S SOLUTIONS: A COMPREHENSIVE REVIEW OF NATURAL TREATMENTS FOR PCOS MANAGEMENT

**Shaffintaj Mohamed Rafik<sup>1,3</sup>, Kannan Raman<sup>1,3\*</sup>, Kavinkumar MC<sup>2,3</sup>, Bharathiraja Anthony Samy<sup>1,3</sup>, Deepen Natarajan<sup>1,3</sup>, Suresh Velayutham<sup>1,3</sup>, Senthilkumar Natesan<sup>1,3</sup>**

<sup>1</sup>Department of Pharmacology, JKKMMRFs Annai JKK Sampoorani Ammal College of Pharmacy, B.Komarapalayam. Tamil Nadu, India - 638183.

<sup>2</sup>Department of Pharmaceutical Chemistry, Vellalar College of Pharmacy, Maruthi Nagar, Thindal, Erode, Tamilnadu – 638012, India.

<sup>3</sup> Affiliated by The Tamil Nadu, Dr.M.G.R. Medical University, Chennai, Tamil Nadu, India.

## **\*Corresponding Address**

Dr. Kannan Raman\*

Mail - kannanraman320@gmail.com

## **ABSTRACT:**

PCOS refers to a hormonal condition that results in enlarged ovaries and little cysts around the periphery. Polycystic ovarian syndrome is manifested by amenorrhea, hirsutism and obesity associated with cysts. PCOS is a syndrome not a disease characterized by a variable clinical features and has potential multiple etiologies. Causes of PCOS was not clearly known. May be the lifestyle changes plays a major role in PCOS, obesity and mainly linked to elevated insulin resistance, which causes diabetes and may leads to cardiovascular disorders and hypertension. Genetics also plays a role in this syndrome. The nutrients involved in treatment and their mechanism of action was also studied. The currently available drugs in the market and their effectiveness in treatment also discussed. This review focus on the various herbal medicines and natural products utilized as a polycystic ovarian syndrome therapy. Focusing drug targets also the molecule that are closely associated with the disease by using In-silico studies. We analyze about the in-vivo studies and role of letrozole as an inducing agent in study of PCOS.

**Key words:** PCOS, Medicinal Plant, letrozole,

## 1. INTRODUCTION

Polycystic ovarian syndrome was initially discovered by Stein and Leventhal in 1935. Stein-Leventhal syndrome is another name for it that is expanded. Polycystic ovarian syndrome was manifested by amenorrhoea, hirsutism and obesity associated with cysts. PCOS is a syndrome not a disease characterized by a variable clinical features and has potential multiple etiologies.[1,2] It is a heterogeneous endocrinopathy that affects the human of the reproductive age. Infertility is a serious problem which women struggle to get pregnant. Here the management helps to lower the body weight, lower the insulin levels, restore fertility and to regularize menstruation. Generally ovarian follicles consist of egg cells that get matured and released during the ovulation.[2] But in PCOS due to hormonal imbalance the ovarian follicles prevent the eggs from maturing and delay or inhibit the ovulation. The polycystic ovary consists of immature multiple cysts and affects the menstrual cycle[3]


### 1.1 EPIDEMIOLOGY

Hyperandrogenism is the major cause of PCOS. Over 80% of women in reproductive age affected with PCOS, among them 70% of women show the clinical symptoms of excessive androgens like hirsutism. 10%-15% of women show acne on their face which is the specific clinical marker of hirsutism[4]. Around 30% of women show unwanted hair growth. Comparing with previous year prevalence is increased about 10-13%. [5]

### 1.2 ETIOLOGY

Causes of PCOS were not clearly known. Maybe the lifestyle changes play a major role in PCOS, obesity and are mostly linked to elevated insulin resistance, which causes diabetes and may lead to cardiovascular disorders and hypertension. Impaired pituitary function causes altered LH/FSH levels leading to hyperandrogenism. Genetic factors like CYP21 gene mutation also play a role in PCOS. Stress also plays a major role in PCOS[6]

### 1.3 PATHPHYSIOLOGY




**Figure 1: Pathophysiology of PCOS**

Increased in frequency of GnRh ( gonadotrophin releasing hormone) pulses and LH(leutinizing hormone) increases, with this LH theca cells are stimulated by insulin to produce androgens. The synergistic action of insulin with androgens decreases the hepatic production of hepatic SHBG, which results in rise in testosterone level. The ovaries of PCOS was 2-5 times than the normal size around 2-9mm in size. [7,8]

#### 1.4 NORMAL OVARY Vs POLYCYSTIC OVARY:

Egg cells are normally found in ovarian follicles and are released during ovulation. Anomalies in hormone levels stop follicles in polycystic ovarian syndrome from developing and maturing to release eggs.[9] Rather, the ovaries become overpopulated with these immature follicles. <sup>1</sup>Twelve or more of these follicles may be present in affected women. With aging, these follicles typically become fewer in number.[10] Certain studies support the theory that the main reproductive symptoms of the illness are typically caused by excess ovarian androgen. In addition to explaining the cutaneous manifestations of PCOS, ovarian hyperandrogenism can also explain all of the histopathologic characteristics of the polycystic ovary: a high intraovarian androgen concentration can explain the polycystic appearance of the ovaries, ovarian enlargement, capsular thickening, thecal/stromal hyperplasia, and luteinization, in addition to enhancing the recruitment of primordial follicles into the pool of growing small pre-antral and antral follicles. Additionally, it can hinder the selection of the dominant follicle. [11]



**Figure 2 : Normal Ovary Vs Polycystic ovary**

## 1.5 GENETICS AND PCOS:

PCOS is associated with four phenotypes: A, B, C, and D. PCOS phenotypes A and B are traditional. Menstrual disruption, elevated insulin secretion and insulin resistance, and an increased risk of metabolic dysfunction are described characteristics of these phenotypes. [12] This phenotype has a higher risk of hepatic steatosis. Additionally, there is a notable increase in anti-Mullerian hormone levels. [13] Ovulatory PCOS is the term used to describe phenotype C, which is defined by high hirsutism scores. Nonhyperandrogenic PCOS, or phenotype D, is typified by normal androgen levels along with marginally raised levels of other endocrine systems and metabolic abnormalities. An increased level of sex hormone binding globulin is one of the endocrine findings. [14] Women who belong to Phenotype D experience periodic aberrations in their usual menstrual cycle. Patients from the same family have varying genetic susceptibilities to different genes.[15,16]

## 1.6 HERBS AS A TREATMENT OF PCOS

Many approaches, such as laparoscopy and allopathic medications, are utilized to treat PCOS. Through a medical technique called laparoscopy, ovarian cysts are removed.[18] Presently, PCOS is treated with medications including nafarelin, troglitazone, clomiphene, metformin, and spironolactone.[19] But if these medications are used for an extended period of time, they can have serious side effects as well, such as irregular menstruation, weight gain, nausea, vomiting, and gastrointestinal problems, as well as increased insulin resistance, poor compliance, ineffectiveness, and more contraindications.[20] Due to its adverse effects, patients with cardiovascular problems, women of reproductive age, obese individuals, and nursing moms are more vulnerable when using these medications.[21] Therefore, it is imperative to find and create medications derived from plants that are far more effective than the current allopathic medications. The usage of herbal remedies by medical practitioners to treat PCOS has changed significantly in recent years. Herbal medications consist of whole plant extracts or any portion of a plant that has a significant therapeutic impact and, in comparison to conventional therapy, less adverse effects. [22] They play a big part in recovery, prevention, and treatment. Herbal medications are intricate treatments that have the potential for both antagonistic and synergistic interactions amongst constituents. [23] They are less likely to have side effects than allopathic medications and are crucial for the treatment of PCOS. It is safer and more effective to treat PCOS and decrease the processes that lead to the formation of cysts in PCOS patients by regularly using herbs. [24] Herbal treatments are currently widely used to treat a variety of chronic illnesses, including PCOS. PCOS may be treated more successfully with the use of natural remedies and dietary changes. Various herbs will work against PCOS in different ways, such as by boosting follicle stimulating hormone (FSH), inhibiting prolactin levels, and having anti-androgenic properties. [25,26]


## 1.7 LETROZOLE INDUCED PCOS

Letrozole is a non-steroidal aromatase inhibitor which decreases the estrogen level. [27] It is specifically used in estrogen sensitive breast cancer. Recent study reveals that the letrozole causes 90% of infertility reporting in an ovulation. [28] This reduces amount of estrogen and increases the FSH level. Increased levels of FSH leads to growth of additional follicles and causes hormonal imbalances in body. [29] FSH stimulates granulosa cell, proliferation and aromatase production. LH stimulates androstenedione production by theca cells that diffuses into granulosa cells, aromatase converts androstenedione to estrogen. Letrozole inhibits the CYP450 aromatase enzyme and decreases the circulating estrogen. [30,31]

## 2. ROLE OF NUTRIENTS IN PCOS:

### 2.1. Inositol

The inositol stereoisomers, myo-inositol (MI) and D-chiro-inositol (DCI), which belongs to class of hexahydroxycyclohexanes, which has the same molecular formula as glucose. [32] Inositol acts as a secondary messenger for many hormones like insulin and follicle stimulating hormone FSH. [33] Any defects in this pathway leads to the impaired insulin sensitivity and causes insulin intolerance. By using inositol the insulin resistance can be treated and hence used in treatment of PCOS.[34,35]




**Figure 3: Inositol**

### 2.2. Vitamin A

Oocyte maturation, steroid metabolism, and antioxidant activity are all supported by vitamin A, a dietary supplement that is composed of retinol, retinoids, and retinoic acid.[36] Theca interna cells treated with trans retinol exhibited elevated levels of dehydroepiandrosterone and mRNA accumulation of cytochrome P450 17 $\alpha$  hydroxylase (CYP17), an enzyme implicated in the generation of androgens and the biosynthesis of retinol.[37] Elevated levels of retinol-binding protein 4 (RBP4) are linked to obesity and impaired glucose metabolism in women with PCOS who are overweight[38] Measurements of RBP4 expression in isolated subcutaneous and omental adipose tissue from PCOS-affected women were reported in another RBP4-based study.[39]The authors proposed that increased 17 $\beta$  estradiol could


upregulate the RBP4 gene, which would then contribute to the changed gonadal and adrenal steroid profile.[40]



**Figure 4: Vitamin A<sup>[41]</sup>**

### 2.3 Alpha-Lipoic Acid (a-LA)


It works on the mechanism of free radical scavenging. It is the important cofactor of citric acid cycle and regulates the body weight. Recent studies reveals that the alpha lipoic acid increases the ovarian functions like decreased ovarian cysts and improved menstrual cycles.[41,42]



**Figure 5: Alpha-Lipoic Acid (a-LA)**

### 2.4 Bioflavanoids


It is made up of plant-found polyphenolic chemicals. Antioxidant, antidiabetic, antiestrogenic, anti-inflammatory, and antiproliferative qualities are demonstrated by flavonoids. [43] They acts be reducing oxidative stress and thereby reduces the cellular damage and decreases the cyst formation.[44]



**Figure 6: Bioflavanoids**

## 2.5 Carnitine

Carnitine is the quaternary ammonium compound which is found in the glucose metabolism, free radical mechanism and fatty acid metabolism. PCOS were reported with low carnitine levels when compared with non PCOS by increasing the carnitine levels PCOS symptoms is reduced and decrease in oxidative stress.[45]



**Figure 7: Carnitine**

## 3. DRUGS USED IN TREATMENT OF PCOS

### 3.1 Oral contraceptives

In approximately two-thirds of hirsute patients, (OCs) inhibit adrenal and ovarian androgen production as well as hair development. [46] There is less ovarian androgen production when the progestin component lowers LH. Lower levels of free testosterone are the consequence of the estrogen component's increased hepatic synthesis of SHBG. Under the skin, estrogens inhibit 5 $\alpha$ -reductase, which reduces the conversion of testosterone to DHT.[47]

### 3.2 Medroxyprogesterone Acetate-

Hirsutism can be effectively treated with oral or intramuscular dose of medroxyprogesterone acetate (MPA). By lowering gonadotropin release and GnRH production, it directly impacts the hypothalamic-pituitary axis by lowering ovarian output of testosterone and estrogen. The levels of free and total androgen are much lower despite a drop in SHBG.[48]

### 3.3 Gonadotropin

The distinction between androgen derived from ovarian and adrenal sources may be made possible by the use of GnRH agonists. In both idiopathic hirsutism and hirsutism owing to PCOS, treatment with leuprolide acetate administered intramuscularly every 28 days reduces hirsutism and hair diameter. A marked and specific suppression of ovarian androgen levels occurs.[49]

### 3.4 Glucocorticoids

Dexamethasone, a glucocorticoid, is used to treat PCOS patients with adrenal hyperandrogenism or combined adrenal and ovarian hyperandrogenism. In the beginning, dexamethasone dosages as low as 0.25 mg administered nightly or every other night are utilized to decrease DHEAS concentrations below 400 µg/dL. Ketoconazole: This medication inhibits the main cytochromes that are steroidogenic. When taken at a modest dosage of 200 mg daily, it can considerably lower testosterone, androstenedione, and estimated free testosterone levels.[50]

### 3.5 Spironolactone

is a particular aldosterone antagonist that binds to aldosterone receptors in the kidney's distal tubular area in a competitive manner. DHT is inhibited competitively at the intracellular receptor level. - An increase in androgen catabolism (with an increase in the peripheral conversion of testosterone to estrone) - Suppression of testosterone production by a decrease in CYP enzymes. The inhibition of 5α-reductase activity in the skin. The usual dosage is 50–100 mg twice a day.[51]

### 3.6 Cyproterone Acetate

With strong antiandrogenic qualities, cyproterone acetate is a synthetic progestin that is produced from 17-OHP. Competitive suppression of DHT and testosterone at the androgen receptor level is the main mechanism of action of cyproterone acetate. ethinyl estradiol 30 to 50 mg daily on cycle days 5 to 26, and cyproterone acetate 100 mg daily on days 5 to 15. Administered in a reverse sequential regimen.[52]

### 3.7 Flutamide

Pure nonsteroidal antiandrogen flutamide is authorized for the treatment of advanced prostate cancer. Its mode of action involves preventing androgens from attaching to their nuclear sites in the targeted tissues. Greater doses (250 mg taken two or three times day) may make up for the decreased potency, even though it has a poorer affinity to the androgen receptor than spironolactone or cyproterone acetate.[53]

### 3.8 Finasteride:

This particular inhibitor of type 2 5α-reductase enzyme activity is called finasteride. Despite having different effects on androgen levels, finasteride (5 mg daily) and spironolactone (100 mg daily) produced a similar significant improvement in hirsutism in a research. After 7.5 mg of finasteride per day for six months, the majority of the hirsutism improvement was observed with finasteride medication.[54]



### 3.9 Intense Insulin

Due to the possibility that hyperinsulinemia contributes to anovulation linked to PCOS. If used alone or in conjunction with other forms of treatment, insulin sensitizers can cause an endocrine balance that favors ovulation and pregnancy. For non-insulin-dependent diabetes, metformin (Glucophage) is a commonly used oral biguanide antihyperglycemic medication [55].

## 4. Plant-based carbon dots (CQDs used for Treatment of PCOS.

Plant-based carbon dots (CQDs) are an intriguing field of research, and their use in medical treatments, including PCOS, is growing. While there are few studies that explicitly link plant-based carbon dots to PCOS therapy, various forms of plant-derived carbon dots have been investigated for their general health benefits and possible therapeutic applications.

S.No	Plant Name	Carbon Dot Name	Mechanism of Action	Reference
1	Moringa oleifera	Moringa-derived Carbon Dots	Antioxidant, anti-inflammatory, and hormonal regulation.	[56]
2	Camellia sinensis	Green Tea Carbon Dots	Antioxidant, anti-inflammatory, and insulin-sensitizing.	[57]
3	Ginkgo biloba	Ginkgo Carbon Dots	Anti-inflammatory and enhances insulin sensitivity.	[58]
4	Curcuma longa	Curcumin Carbon Dots	Anti-inflammatory, antioxidant, and insulin regulation	[59]
5	Coriandrum sativum	Coriander Carbon Dots	Antioxidant, anti-inflammatory, and supports hormonal balance.	[60]
6	Coffea arabica	Coffee Bean Carbon Dots	Antioxidant, anti-inflammatory, and regulates glucose metabolism.	[61]
7	Graptopetalum paraguayense	Graptopetalum Carbon Dots	Antioxidant and helps in metabolic regulation	[62]
8	Hibiscus sabdariffa	Hibiscus Carbon Dots	Antioxidant and supports hormonal balance.	[63]
9	Boswellia serrata	Boswellia Carbon Dots	Anti-inflammatory and enhances insulin sensitivity.	[64]
10	Echinacea purpurea	Echinacea Carbon Dots	Antioxidant and immune-modulating effects.	[65]

11	Aloe vera	Aloe Carbon Dots	Antioxidant, anti-inflammatory, and insulin regulation.	[66]
12	Thymus vulgaris	Thyme Carbon Dots	Antioxidant, anti-inflammatory, and insulin regulation.	[67]
13	Nigella sativa	Nigella Carbon Dots	Anti-inflammatory, antioxidant, and enhances insulin sensitivity.	[68]
14	Rosmarinus officinalis	Rosemary Carbon Dots	Antioxidant and supports metabolic processes.	[69]
15	Allium sativum	Garlic Carbon Dots	Antioxidant, anti-inflammatory, and helps in metabolic regulation.	[70]
16	Bacopa monnieri	Bacopa Carbon Dots	Neuroprotective, anti-inflammatory, and regulates hormonal imbalance.	[71]
17	Cinnamomum verum	Cinnamon Carbon Dots	Antioxidant, anti-inflammatory, and enhances glucose metabolism.	[72]
18	Zingiber officinale	Ginger Carbon Dots	Anti-inflammatory, antioxidant, and supports metabolic health.	[73]
19	Piper nigrum	Black Pepper Carbon Dots	Enhances bioavailability of other compounds and supports metabolic functions.	[74]
20	Silybum marianum	Milk Thistle Carbon Dots	Antioxidant and supports liver health and hormonal balance.	[75]
21	Lippia citriodora	Lemon Verbena Carbon Dots	Antioxidant and anti-inflammatory, supports metabolic health.	[76]
22	Prunella vulgaris	Self-Heal Carbon Dots	Antioxidant and supports metabolic and immune health.	[77]
23	Mentha piperita	Peppermint Carbon Dots	Antioxidant and supports digestive and metabolic functions.	[78]
24	Acer saccharum	Maple Leaf	Antioxidant and supports	[79]

		Carbon Dots	overall metabolic balance.	
25	Malva sylvestris	Mallow Carbon Dots	Anti-inflammatory and supports metabolic health.	[80]

## 5. Role of natural product in PCOS

Natural products play a significant role in managing Polycystic Ovary Syndrome (PCOS) by providing anti-inflammatory, antioxidant, and insulin-sensitizing effects. Compounds found in herbs, fruits, and vegetables can help regulate hormonal imbalances, improve metabolic profiles, and alleviate symptoms. Their use as complementary therapies offers a holistic approach to PCOS management alongside conventional treatments.

Herb/Plant	Mechanism of Action	References
Spearmint ( <i>Mentha spicata</i> )	Anti-androgenic effects, reduces hirsutism.	[81]
Cinnamon ( <i>Cinnamomum cassia</i> )	Improves insulin sensitivity, regulates blood glucose levels.	[82]
Vitex ( <i>Vitex agnus-castus</i> )	Regulates menstrual cycles, balances hormones.	[83]
Licorice ( <i>Glycyrrhiza glabra</i> )	Anti-androgenic effects, may reduce elevated testosterone levels.	[84]
Fenugreek ( <i>Trigonella foenum-graecum</i> )	Enhances insulin sensitivity, supports glucose metabolism.	[85]
Rehmannia ( <i>Rehmannia glutinosa</i> )	Supports endocrine health, alleviates PCOS symptoms.	[86]
Astragalus ( <i>Astragalus membranaceus</i> )	Supports endocrine function, enhances immune health.	[87]
Shatavari ( <i>Asparagus racemosus</i> )	Supports female reproductive health, balances hormones.	[88]
Dandelion ( <i>Taraxacum officinale</i> )	Anti-inflammatory, supports liver function.	[89]
Green Tea ( <i>Camellia sinensis</i> )	Rich in antioxidants, improves insulin sensitivity.	[90]
Ginger ( <i>Zingiber officinale</i> )	Reduces inflammation, regulates blood sugar levels.	[91]
Turmeric ( <i>Curcuma longa</i> )	Contains curcumin, anti-inflammatory, supports hormonal balance.	[92]
Burdock Root ( <i>Arctium lappa</i> )	Supports liver function, balances hormones.	[93]
Dong Quai ( <i>Angelica sinensis</i> )	Regulates menstrual cycles, alleviates menstrual discomfort.	[94]
Maca Root ( <i>Lepidium</i>	Balances hormones, improves energy levels.	[95]

meyenii)		
Chaste Tree (Vitex agnus-castus)	Normalizes menstrual cycles, reduces PMS symptoms.	[96]
Hawthorn (Crataegus spp.)	Supports cardiovascular health, may help with hypertension.	[97]
Aloe Vera (Aloe barbadensis)	Supports digestive health, has anti-inflammatory effects.	[98]
Gotu Kola (Centella asiatica)	Improves circulation, supports cognitive function.	[99]
Ginkgo Biloba (Ginkgo biloba)	Improves blood circulation, supports cognitive health.	[100]
Black Cohosh (Actaea racemosa)	Regulates hormones, alleviates menstrual symptoms.	[101]
Evening Primrose Oil (Oenothera biennis)	Contains gamma-linolenic acid, supports hormonal balance.	[102]
Red Clover (Trifolium pratense)	Contains phytoestrogens, supports hormonal balance.	[103]
Motherwort (Leonurus cardiaca)	Supports reproductive health, regulates menstrual cycles.	[104]
Hops (Humulus lupulus)	Contains phytoestrogens, helps with hormone balance.	[105]
Psyllium Husk (Plantago ovata)	Supports digestive health, may help with glucose regulation.	[106]
Jasmine (Jasminum sambac)	Offers calming effects, supports reproductive health.	[107]
Sarsaparilla (Smilax officinalis)	Potential hormone-balancing properties.	[108]
Kudzu (Pueraria lobata)	Contains phytoestrogens, helps with hormone balance.	[109]
Holy Basil (Ocimum sanctum)	Reduces stress, supports endocrine health.	[110]
Clover (Trifolium spp.)	Contains isoflavones, supports hormonal balance.	[111]
Licorice Root (Glycyrrhiza glabra)	Balances hormones, supports adrenal health.	[112]

## CONCLUSION:

Polycystic Ovarian Syndrome (PCOS) is one of the most common female endocrine disorders which may leads to infertility. Herbal drugs have promising role in treatment of PCOS and shows steady effect with minimal side effects. Herbal drugs enhance immunity of the body also regularize menstrual cycle without fluctuating hormonal level. The mechanisms underlying the beneficial effects of herbal medicines on PCOS were found to be associated with anti-inflammation, anti-oxidative stress, inhibition of autophagy and/or apoptosis, and ovarian nerve growth factor reduction. Herbal medicines and Natural Carbon dots are thought to be promising resources in the development of effective therapeutic agents for PCOS.

Further studies that include methodological quality assessment and quantitative synthesis of outcomes.

## REFERENCES:

1. Umland EM, Weinstein LC, Buchanan EM. Pharmacotherapy: A Pathophysiologic Approach.
2. Lin LH, Baracat MC, Maciel GA, Soares Jr JM, Baracat EC. Androgen receptor gene polymorphism and polycystic ovary syndrome. *International Journal of Gynecology & Obstetrics*. 2013 Feb 1;120(2):115-8.
3. Aubuchon M, Legro RS. Polycystic ovary syndrome: current infertility management. *Clinical obstetrics and gynecology*. 2011 Dec 1;54(4):675-84..
4. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 108: polycystic ovary syndrome. *Obstetrics & Gynecology*. 2009;114(4):936.
5. McFarland C. Treating polycystic ovary syndrome and infertility. *MCN: The American Journal of Maternal/Child Nursing*. 2012 Mar 1;37(2):116-21.
6. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. *European journal of endocrinology*. 2002 Dec;147(6):717-25.
7. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. *Endocrine*. 2006 Aug;30:19-26.
8. Urbanek M. The genetics of the polycystic ovary syndrome. *Nature clinical practice Endocrinology & metabolism*. 2007 Feb;3(2):103-11.
9. Terry NL, Ryan ME. Polycystic Ovary Syndrome (PCOS) 2012. Bethesda, Md: National Institutes of Health Library; 2012.
10. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. *The Journal of Clinical Endocrinology & Metabolism*. 2006 Jan 1;91(1):48-53
11. Brower M, Brennan K, Pall M, Azziz R. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. *The Journal of Clinical Endocrinology & Metabolism*. 2013 Dec 1;98(12):E1967-71.
12. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and sterility*. 2016 Jul 1;106(1):6-15.
13. Goverde AJ, Van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. *Human Reproduction*. 2009 Mar 1;24(3):710-7.
14. Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2013 Sep 1;170(1):157-61.

- 15 Di Fede G, Mansueto P, Longo RA, Rini G, Carmina E. Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. *Fertility and sterility*. 2009 May 1;91(5):1853-6.
- 16 Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2009 Nov;116(12):1633-9.
- 17 Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Macut D, Bjekic-Macut J, Marthopoulos A, Katsikis I. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. *Hormones*. 2015 Jul;14:431-7.
- 18 Cupisti S, Haeberle L, Schell C, Richter H, Schulze C, Hildebrandt T, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids. *Experimental and clinical endocrinology & diabetes*. 2011 May 6:502-8.
- 19 Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Macut D, Bjekic-Macut J, Marthopoulos A, Katsikis I. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. *Hormones*. 2015 Jul;14:431-7.
- 20 Wijeyaratne CN, Seneviratne RD, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N, Yapa C, Seneviratne RD, Balen AH. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. *Human Reproduction*. 2011 Jan 1;26(1):202-13.
- 21 Faghfoori Z, Fazelian S, Shadnough M, Goodarzi R. Nutritional management in women with polycystic ovary syndrome: A review study. *Diabetes & metabolic syndrome: Clinical research & reviews*. 2017 Nov 1;11:S429-32.
- 22 Farshchi H, Rane A, Love A, Kennedy RL. Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. *Journal of obstetrics and gynaecology*. 2007 Jan 1;27(8):762-73.
- 23 Mansour A, Hosseini S, Larijani B, Mohajeri-Tehrani MR. Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome. *EXCLI journal*. 2016;15:551.
- 24 Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. *The American journal of clinical nutrition*. 2007 Mar 1;85(3):688-94.
- 25 Eslamian G, Hekmatdoost A. Nutrient patterns and risk of polycystic ovary syndrome. *Journal of reproduction & infertility*. 2019 Jul;20(3):161.
- 26 Szczuko M, Skowronek M, Zapalowska-Chwyc M, Starczewski A. Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). *Roczniki państwowego zakładu higieny*. 2016;67(4).
- 27 Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HE, Amer S. The role of chronic inflammation in polycystic ovarian syndrome—a systematic review and meta-analysis. *International journal of molecular sciences*. 2021 Mar 8;22(5):2734.

- 28 Zuo M, Liao G, Zhang W, Xu D, Lu J, Tang M, Yan Y, Hong C, Wang Y. Effects of exogenous adiponectin supplementation in early pregnant PCOS mice on the metabolic syndrome of adult female offspring. *Journal of Ovarian Research*. 2021 Dec;14(1):1-2.
- 29 Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. *International Scholarly Research Notices*. 2013;2013.
- 30 Kempegowda P, Melson E, Manolopoulos KN, Arlt W, O'Reilly MW. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. *Therapeutic advances in endocrinology and metabolism*. 2020 Jun;11:2042018820934319.
- 31 González F, Considine RV, Abdelhadi OA, Acton AJ. Oxidative stress in response to saturated fat ingestion is linked to insulin resistance and hyperandrogenism in polycystic ovary syndrome. *The Journal of Clinical Endocrinology & Metabolism*. 2019 Nov;104(11):5360-71.
- 32 González F, Considine RV, Abdelhadi OA, Acton AJ. Saturated fat ingestion promotes lipopolysaccharide-mediated inflammation and insulin resistance in polycystic ovary syndrome. *The Journal of Clinical Endocrinology & Metabolism*. 2019 Mar;104(3):934-46.
- 33 American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the diagnosis and treatment of hyperandrogenic disorders. *Endocr Practice*. 2001;7:121-34.
- 34 Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. *Therapeutic Advances in Endocrinology and Metabolism*. 2020 Jul;11:2042018820938305.
- 35 Seow KM, Chang YW, Chen KH, Juan CC, Huang CY, Lin LT, Tsui KH, Chen YJ, Lee WL, Wang PH. Molecular mechanisms of laparoscopic ovarian drilling and its therapeutic effects in polycystic ovary syndrome. *International journal of molecular sciences*. 2020 Oct 31;21(21):8147.
- 36 Shpakov AO. Improvement effect of metformin on female and male reproduction in endocrine pathologies and its mechanisms. *Pharmaceuticals*. 2021 Jan 8;14(1):42.
- 37 Jia LY, Feng JX, Li JL, Liu FY, Xie LZ, Luo SJ, Han FJ. The complementary and alternative medicine for polycystic ovary syndrome: A review of clinical application and mechanism. *Evidence-Based Complementary and Alternative Medicine*. 2021 Feb 26;2021:1-2.
- 38 Panda SR, Jain M, Jain S, Saxena R, Hota S. Effect of orlistat versus metformin in various aspects of polycystic ovarian syndrome: a systematic review of randomized control trials. *The Journal of Obstetrics and Gynecology of India*. 2018 Oct;68:336-43.
- 39 Durmus U, Duran C, Ecirli S. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. *Journal of endocrinological investigation*. 2017 May;40:487-97.
- 40 Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ, Network IP. Erratum. Recommendations from the international evidence-based

- guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction (Oxford, England). 2019 Feb;34(2):
- 41 Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertility and sterility. 2002 Nov 1;78(5):1001-4.
  - 42 Kwon CY, Cho IH, Park KS. Therapeutic effects and mechanisms of herbal medicines for treating polycystic ovary syndrome: A review. Frontiers in Pharmacology. 2020 Aug 12;11:1192.
  - 43 Goswami PK, Khale A, Ogale S. Natural remedies for polycystic ovarian syndrome (PCOS): a review. International journal of pharmaceutical and phytopharmacological research. 2012;1(6):396-402.
  - 44 Kwon CY, Lee B, Park KS. Oriental herbal medicine and moxibustion for polycystic ovary syndrome: a meta-analysis. Medicine. 2018 Oct;97(43).
  - 45 Hoberg E, Orjala J, Meier B, Sticher O. Diterpenoids from the fruits of *Vitex agnus-castus*. Phytochemistry. 1999 Dec 1;52(8):1555-8.
  - 46 Jelodar G, Askari K. Effect of *Vitex agnus-castus* fruits hydroalcoholic extract on sex hormones in rat with induced polycystic ovary syndrome (PCOS). Physiology and Pharmacology. 2012 Apr 10;16(1):62-9.
  - 47 Bahmani M, Shokri S, Akhtar ZN, Abbaszadeh S, Manouchehri A. The effect of pomegranate seed oil on human health, especially epidemiology of polycystic ovary syndrome; a systematic review. JBRA assisted reproduction. 2022 Oct;26(4):631.
  - 48 Gupte PA, Khade KN, Wagh GN, Deshmukh CS, Pandit VA, Bhalerao SS. Effect of combination of *Curcuma longa* with *Embolica officinalis* in females with polycystic ovarian syndrome: An open-label, randomized active-controlled, exploratory clinical study. Journal of Diabetology. 2023 Jul 1;14(3):126-34.
  - 49 Shamsi M, Nejati V, Najafi G, Pour SK. Protective effects of licorice extract on ovarian morphology, oocyte maturation, and embryo development in PCOS-induced mice: An experimental study. International journal of reproductive biomedicine. 2020 Oct;18(10):865.
  - 50 Ataabadi MS, Alaei S, Bagheri MJ, Bahmanpoor S. Role of essential oil of *Mentha spicata* (Spearment) in addressing reverse hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model. Advanced pharmaceutical bulletin. 2017 Dec;7(4):651.
  - 51 Akintoye OO, Ajibare AJ, Omotuyi IO. Virgin coconut oil reverses behavioral phenotypes of letrozole-model of PCOS in Wistar rats via modulation of NRF2 upregulation. Journal of Taibah University Medical Sciences. 2023 Aug;18(4):831.
  - 52 Miller LG, Murray WJ. Herbal medicinals: a clinician's guide. (No Title). 2005.
  - 53 Pournaderi PS, Yaghmaei P, Hejazi SH, Noormohammadi Z, Khodaei HR. The effects of ginger extract on cyclooxygenase-2 gene expression in polycystic ovary syndrome rats. Journal of Basic Research in Medical Sciences. 2019 Sep 10;6(4):37-44.
  - 54 Krishnan J, Dash M, Babu S, Kirubamani H. Phytochemical And Pharmacological Activity Of *Trigonella Foeniculum* Graceum And Its Impact On Polycystic Ovarian



- Syndrome: A Comprehensive Review. *Journal of Pharmaceutical Negative Results*. 2022 Dec 31;4616-23.
- 55 Sadrefozalayi S, Farokhi F. Effect of the aqueous extract of *Foeniculum vulgare* (fennel) on the kidney in experimental PCOS female rats. *Avicenna journal of phytomedicine*. 2014 Mar;4(2):110.
  - 56 Abdull Razis AF, Ibrahim MD, Kntayya SB. Health benefits of *Moringa oleifera*. *Asian pacific journal of cancer prevention*. 2014;15(20):8571-6.
  - 57 Vieira Senger AE, Schwanke CH, Gomes I, Valle Gottlieb MG. Effect of green tea (*Camellia sinensis*) consumption on the components of metabolic syndrome in elderly. *The journal of nutrition, health & aging*. 2012 Nov;16:738-42.
  - 58 Luo WK, Zhang LL, Yang ZY, Guo XH, Wu Y, Zhang W, Luo JK, Tang T, Wang Y. Herbal medicine derived carbon dots: synthesis and applications in therapeutics, bioimaging and sensing. *Journal of Nanobiotechnology*. 2021 Dec;19:1-30.
  - 59 Pal T, Mohiyuddin S, Packirisamy G. Facile and green synthesis of multicolor fluorescence carbon dots from curcumin: in vitro and in vivo bioimaging and other applications. *ACS omega*. 2018 Jan 23;3(1):831-43.
  - 60 Hu J, Jia W, Yu X, Yan C, White JC, Liu J, Shen G, Tao S, Wang X. Carbon dots improve the nutritional quality of coriander (*Coriandrum sativum* L.) by promoting photosynthesis and nutrient uptake. *Environmental Science: Nano*. 2022;9(5):1651-61.
  - 61 Duangsodsri T. *Phenolic compounds in the response of Coffea arabica L. to abiotic stresses* (Doctoral dissertation, Université Montpellier).
  - 62 Chen SJ, Yen CH, Liu JT, Tseng YF, Lin PT. Anti-inflammatory effect of water extracts of *Graptopetalum paraguayense* supplementation in subjects with metabolic syndrome: a preliminary study. *Journal of the Science of Food and Agriculture*. 2016 Mar;96(5):1772-6.
  - 63 Abdelhameed RE, Abdalla H, Ibrahim MA. Unique properties of titanium dioxide quantum dots assisted regulation of growth and biochemical parameters of *Hibiscus sabdariffa* plants. *BMC Plant Biology*. 2024 Feb 16;24(1):112.
  - 64 Cometa S, Busto F, Scalia AC, Castellaneta A, Gentile P, Cochis A, Manfredi M, Borrini V, Rimondini L, De Giglio E. Effectiveness of gellan gum scaffolds loaded with *Boswellia serrata* extract for in-situ modulation of pro-inflammatory pathways affecting cartilage healing. *International Journal of Biological Macromolecules*. 2024 Oct 1;277:134079.
  - 65 Brink M. Evaluation of Botanical Extracts with Immune Enhancing and/or Anti-HIV Activity in vitro. University of Johannesburg (South Africa); 2002.
  - 66 Praseetha PK, Vibala BV, Sreedevy K, Vijayakumar S. Aloe-vera conjugated natural Carbon Quantum dots as Bio-enhancers to accelerate the repair of chronic wounds. *Industrial Crops and Products*. 2021 Dec 15;174:114152.
  - 67 Bayat A, Masoum S, Hosseini ES. Natural plant precursor for the facile and eco-friendly synthesis of carbon nanodots with multifunctional aspects. *Journal of Molecular Liquids*. 2019 May 1;281:134-40.
  - 68 Sharma N, Yun K. Dual sensing of tetracycline and l-Lysine using green synthesized carbon dots from *Nigella sativa* seeds. *Dyes and Pigments*. 2020 Nov 1;182:108640.

- 69 Sadgrove NJ. The new paradigm for androgenetic alopecia and plant-based folk remedies: 5 $\alpha$ -reductase inhibition, reversal of secondary microinflammation and improving insulin resistance. *Journal of ethnopharmacology*. 2018 Dec 5;227:206-36.
- 70 Ojo OA, Nwafor-Ezeh PI, Rotimi DE, Iyobhebhe M, Ogunlakin AD, Ojo AB. Apoptosis, inflammation, and oxidative stress in infertility: A mini review. *Toxicology Reports*. 2023 Jan 1;10:448-62.
- 71 Subhan S, Bagchi M, editors. *Phytopharmaceuticals for brain health*.
- 72 Ainehchi N, Khaki A, Farshbaf-Khalili A, Hammadeh M, Ouladsahebmadarek E. The effectiveness of herbal mixture supplements with and without clomiphene citrate in comparison to clomiphene citrate on serum antioxidants and glycemic biomarkers in women with polycystic ovary syndrome willing to be pregnant: a randomized clinical trial. *Biomolecules*. 2019 Jun 3;9(6):215.
- 73 Sethiya A, Teli P, Agarwal DK, Agarwal S. Insight View on the Pharmacological Potential and Bio-active Components of Ginger. *Letters in Drug Design & Discovery*. 2024 Sep 1;21(12):2195-209.
- 74 Singh S, Arya V, Mishra RK, Rajput SK, Dhanasekaran M. Nanotechnology in the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Scoping Analysis to Improve Patient Care. *Next Research*. 2024 Aug 9:100004.
- 75 Akhtar MN, Saeed R, Saeed F, Asghar A, Ghani S, Ateeq H, Ahmed A, Rasheed A, Afzaal M, Waheed M, Hussain B. Silymarin: a review on paving the way towards promising pharmacological agent. *International Journal of Food Properties*. 2023 Sep 22;26(1):2256-72.
- 76 Masullo M, Montoro P, Mari A, Pizza C, Piacente S. Medicinal plants in the treatment of women's disorders: Analytical strategies to assure quality, safety and efficacy. *Journal of pharmaceutical and biomedical analysis*. 2015 Sep 10;113:189-211.
- 77 Sar S, Banerjee T, Kumar A, Baidya A, Saha S, Mondal J, Chaki R, Halder AK, Ghosh N. Role of Natural Polysaccharides in the Management of Lifestyle Diseases. In *Role of Herbal Medicines: Management of Lifestyle Diseases* 2024 Feb 27 (pp. 415-441). Singapore: Springer Nature Singapore.
- 78 Brice-Ytsma H, McDermott A. *Herbal Medicine in Treating Gynaecological Conditions*. Aeon Books; 2020 Jan 30.
- 79 Tariq L. *Comparative Insilico Analysis of Fenugreek and Flaxseed for Drug Development in Polycystic Ovary Syndrome* (Doctoral dissertation, CAPITAL UNIVERSITY).
- 80 Malik K, Ahmad M, Öztürk M, Altay V, Zafar M, Sultana S. Medicinal Plants Used for Gynecological Disorders. In *Herbals of Asia: Prevalent Diseases and Their Treatments* 2021 Nov 17 (pp. 105-172). Cham: Springer International Publishing.
- 81 Alizadeh F, Ramezani M, Piravar Z. Effects of *Stachys sylvatica* hydroalcoholic extract on the ovary and hypophysis-gonadal axis in a rat with polycystic ovary syndrome. *Middle East Fertility Society Journal*. 2020 Dec;25(1):1-7.
- 82 Poornima R, Saranya P, Bhuvaneshwari S, Averal HI. Evaluation of *Pergularia daemia* and metformin in the treatment of PCOS in testosterone propionate induced albino wistar rats (*Rattus norvegicus*). *Int J Sci Res Pub*. 2015 Nov;5:503-9.

- 83 Smyka M, Grzechocińska B, Wielgoś M. The role of lifestyle changes in the treatment of polycystic ovary syndrome. *Neuroendocrinol Lett.* 2017 Jan 1;38:521-7.
- 84 Fan CW, Cieri-Hutcherson NE, Hutcherson TC. Systematic review of black cohosh (*Cimicifuga racemosa*) for management of polycystic ovary syndrome-related infertility. *Journal of Pharmacy Practice.* 2022 Dec;35(6):991-9.
- 85 Demirel MA, Ilhan M, Suntar I, Keles H, Akkol EK. Activity of *Corylus avellana* seed oil in letrozole-induced polycystic ovary syndrome model in rats. *Revista Brasileira de Farmacognosia.* 2016 Jan;26:83-8.
- 86 Demirel MA, Ilhan M, Suntar I, Keles H, Akkol EK. Activity of *Corylus avellana* seed oil in letrozole-induced polycystic ovary syndrome model in rats. *Revista Brasileira de Farmacognosia.* 2016 Jan;26:83-8.
- 87 Alizadeh F, Azarnia M, Mirabolghasemi G, Karampoor P. Effect of fruit heracleum persicum extract on changes in serum levels of sex hormones in rats with polycystic ovary syndrome (PCOS). *Armaghane danesh.* 2015 Apr 10;20(1):31-42.
- 88 Ghafurniyan H, Azarnia M, Nabiuni M, Karimzadeh L. The effect of green tea extract on reproductive improvement in estradiol valerate-induced polycystic ovarian syndrome in rat. *Iranian journal of pharmaceutical research: IJPR.* 2015;14(4):1215.
- 89 Bardei K. The effects of hydro-alcoholic extract of raspberry fruit on ovarian follicles and serum parameters in poly cystic ovary syndrome-induced rat. *Armaghane danesh.* 2015 Feb 10;19(11):955-68.
- 90 Ghafurniyan H, Azarnia M, Nabiuni M, Karimzadeh L. The effect of green tea extract on reproductive improvement in estradiol valerate-induced polycystic ovarian syndrome in rat. *Iranian journal of pharmaceutical research: IJPR.* 2015;14(4):1215.
- 91 Guang HJ, Li F, Shi J. Letrozole for patients with polycystic ovary syndrome: A retrospective study. *Medicine.* 2018 Nov;97(44).
- 92 Jirge PR, Patil RS. Comparison of endocrine and ultrasound profiles during ovulation induction with clomiphene citrate and letrozole in ovulatory volunteer women. *Fertility and sterility.* 2010 Jan 1;93(1):174-83.
- 93 Rajan RK, Balaji B. *sPharmaceutical biology.* 2017 Jan 1;55(1):242-
- 94 Hlebowicz J, Darwiche G, Björgell O, Almér LO. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. *The American journal of clinical nutrition.* 2007 Jun 1;85(6):1552-6.
- 95 Bisinotto RS, Castro LO, Pansani MB, Narciso CD, Martinez N, Sinedino LD, Pinto TL, Van de Burgwal NS, Bosman HM, Surjus RS, Thatcher WW. Progesterone supplementation to lactating dairy cows without a corpus luteum at initiation of the Ovsynch protocol. *Journal of Dairy science.* 2015 Apr 1;98(4):2515-28.
- 96 Bisinotto RS, Castro LO, Pansani MB, Narciso CD, Martinez N, Sinedino LD, Pinto TL, Van de Burgwal NS, Bosman HM, Surjus RS, Thatcher WW. Progesterone supplementation to lactating dairy cows without a corpus luteum at initiation of the Ovsynch protocol. *Journal of Dairy science.* 2015 Apr 1;98(4):2515-28.
- 97 Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Bassar R, Lavoie MA, Guertin MC. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. *Jama.* 2007 Apr 18;297(15):1675-82.

- 98 Surjus RS, Prata AB, Borsato M, Mattos FC, da Silveira MC, Mourao GB, Pires AV, Wiltbank MC, Sartori R. In vivo embryo production in cows superovulated 1 or 2 days after ovum pick-up. *Reproduction, Fertility and Development*. 2014 May 6;26(4):527-32.
- 99 Kumar P, Wu H, McBride JL, Jung KE, Hee Kim M, Davidson BL, Kyung Lee S, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. *Nature*. 2007 Jul 5;448(7149):39-43.
- 100 Richter S, Peitzsch M, Rapizzi E, Lenders JW, Qin N, de Cubas AA, Schiavi F, Rao JU, Beuschlein F, Quinkler M, Timmers HJ. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. *The Journal of Clinical Endocrinology & Metabolism*. 2014 Oct 1;99(10):3903-11.
- 101 Marinho F, de Azeredo Passos VM, Malta DC, França EB, Abreu DM, Araújo VE, Bustamante-Teixeira MT, Camargos PA, da Cunha CC, Duncan BB, Felisbino-Mendes MS. Burden of disease in Brazil, 1990–2016: a systematic subnational analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2018 Sep 1;392(10149):760-75.
- 102 Hainsworth JD, Burris III HA, Morrissey LH, Litchy S, Scullin Jr DC, Bearden III JD, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. *Blood, The Journal of the American Society of Hematology*. 2000 May 15;95(10):3052-6.
- 103 Duffy MJ. Evidence for the clinical use of tumour markers. *Annals of clinical biochemistry*. 2004 Sep 1;41(5):370-7.
- 104 Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, Wei S, Deng Y, Liu J, Liu HG, Yang M. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chinese medical journal*. 2020 May 1;133(09):1032-8.
- 105 Dowsett L, Porras AR, Kruszka P, Davis B, Hu T, Honey E, Badoe E, Thong MK, Leon E, Girisha KM, Shukla A. Cornelia de Lange syndrome in diverse populations. *American Journal of Medical Genetics Part A*. 2019 Feb;179(2):150-8.
- 106 Mac Sweeney R, McAuley DF. Acute respiratory distress syndrome. *The Lancet*. 2016 Nov 12;388(10058):2416-30.
- 107 Jiang L, McGreer ID, Fan X, Strauss MA, Bañados E, Becker RH, Bian F, Farnsworth K, Shen Y, Wang F, Wang R. The final SDSS high-redshift quasar sample of 52 quasars at  $z > 5.7$ . *The Astrophysical Journal*. 2016 Dec 19;833(2):222.
- 108 Akinmoladun VI, Edem FV, Popoola OA, Arinola OG. Global DNA methylation profile of head and neck squamous carcinoma patients at the university college hospital, Ibadan, Nigeria. *International Research Journal of Oncology*. 2020 Jun 2;3(2):13-9.
- 109 Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, Wu Y, Liu M. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. *JAMA network open*. 2021 Dec 1;4(12):e2137257

- 110 Harris CR, Millman KJ, Van Der Walt SJ, Gommers R, Virtanen P, Cournapeau D, Wieser E, Taylor J, Berg S, Smith NJ, Kern R. Array programming with NumPy. *Nature*. 2020 Sep 17;585(7825):357-62.
- 111 Singh N, Manshian B, Jenkins GJ, Griffiths SM, Williams PM, Maffeis TG, Wright CJ, Doak SH. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. *Biomaterials*. 2009 Aug 1;30(23-24):3891-914.
- 112 El-Sayed ES, Yuan YD, Zhao D, Yuan D. Zirconium metal–organic cages: synthesis and applications. *Accounts of Chemical Research*. 2022 May 17;55(11):1546-60.